Cannabis shows promise for IBD symptoms in the lab but has not yet delivered in clinical trials

In animal models, both exogenous cannabinoids and modulation of the endocannabinoid system consistently improved colitis. However, this did not translate to human IBD in the few clinical trials conducted. The largest study was limited by poor medication tolerance due to THC content. Cannabis use surveys show patients report symptom improvements, but controlled evidence is lacking.

Narrative review synthesizing preclinical studies (chemical colitis models, genetic knockout models, enzyme inhibition studies), clinical surveys of cannabis use in IBD, and the limited clinical trial data available.

IBD patients are already using cannabis for symptom relief based on anecdotal reports, but the disconnect between strong animal data and weak human trial results highlights a critical evidence gap. Understanding why preclinical promise has not translated to clinical benefit is essential.

IBD represents a common pattern in cannabinoid research: promising animal data, strong patient interest, widespread self-medication, but minimal controlled clinical evidence. The THC tolerance issue suggests CBD-focused or alternative delivery approaches may be needed.

Very few clinical trials have been conducted in human IBD. Animal colitis models (mainly chemical-induced) do not perfectly represent human Crohn's or ulcerative colitis. Survey data on cannabis use is subject to recall and reporting bias.